ArticleAsian Pacific journal of cancer prevention : APJCP2020
Cost of Treatment for Cervical Cancer in India.
Article in Asian Pacific journal of cancer prevention : APJCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Cost-effectiveness of cervical cancer screening among women living with HIV in India: study protocol.BMJ open · 2026Article
- Vaccinating girls, abandoning women: the financing asymmetry between HPV immunization and the cervical cancer treatment cascade in low- and middle-income countries.Frontiers in oncology · 2026Article
- Young adult immunization initiative (YUVA/YAII): A policy framework for India's life-course vaccination strategy.The Indian journal of medical research · 2025Article
- Financial burden of cancer in Nepal: Factors associated with annual cost and catastrophic health expenditure.PloS one · 2025Article
- Cost Analysis Related to Diagnosis, Treatment and Management of Cervical Cancer in Antigua and Barbuda: A Prevalence-Based Cost-of-Illness Study.International journal of environmental research and public health · 2024Article
- IAPSM's Position Paper on the Human Papilloma Virus (HPV) Vaccine for Adult Immunization in India.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2024Article
- Burden of cervical cancer in India: estimates of years of life lost, years lived with disability and disability adjusted life years at national and subnational levels using the National Cancer Registry Programme data.Reproductive health · 2024Article
- Catastrophic health expenditure and distress financing of breast cancer treatment in India: evidence from a longitudinal cohort study.International journal for equity in health · 2024Article
- The economic burden of cervical cancer on women in Uganda: Findings from a cross-sectional study conducted at two public cervical cancer clinics.PLOS global public health · 2024Article
- Financial toxicity in cancer palliative care in India: Addressing existence and beyond - Seeking remedies for a balanced financial journey.Ecancermedicalscience · 2024Article
- Estimation of economic burden throughout course of cervical squamous intraepithelial lesion and cervical cancer in China: A nationwide multicenter cross-sectional study.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Cancer care and economic burden-A narrative review.Journal of family medicine and primary care · 2023Review
- Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India.BMJ global health · 2023Article
- Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report.Medical oncology (Northwood, London, England) · 2023Article
- Audio-Visual Training Improves Awareness and Willingness of Cervical Cancer Screening among Healthy Indian Women: Findings from a Survey.South Asian journal of cancer · 2023Article
- Financial toxicity of cancer treatment in India: towards closing the cancer care gap.Frontiers in public health · 2023Article
- Catastrophic expenditure and treatment attrition in patients seeking comprehensive colorectal cancer treatment in India: A prospective multicentre study.The Lancet regional health. Southeast Asia · 2022Article
- Cost of Surgical Care at Public Sector District Hospitals in India: Implications for Universal Health Coverage and Publicly Financed Health Insurance Schemes.PharmacoEconomics - open · 2022Article
- Ensuring quality in contextualised cancer management guidelines for resource-constraint settings: using a systematic approach.BMJ global health · 2022Article
- Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.Applied health economics and health policy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCervical cancer is a major public health problem in India leading to high economic burden, which is disproportionately borne by the patients as out-of-pocket expenditure (OOPE). Several publicly financed health insurance schemes (PFHIs) in India cover the treatment for cervical cancer. However, the provider payment rates for health benefit packages (HBP) under these PFHIs are not based on scientific evidence. We undertook this study to estimate the cost of services provided for treatment of cervical cancer and cost of the package of care for cervical cancer in India.
methodsThe study was undertaken at a large public tertiary hospital in North India. The health system cost was assessed using a mixed micro-costing approach. The data were collected for all the resources utilized during service delivery for cervical cancer patients. To evaluate the OOPE, randomly selected 248 patients were interviewed following the cost of illness approach. Logistic regression was used to assess the factors associated with catastrophic health expenditure (CHE).
resultsHealth system cost for different cervical cancer treatment modalities i.e. radiotherapy, brachytherapy, chemotherapy and surgery, ranges from INR 19,494 to 41,388 (USD 291 - 617). Furthermore, patients spent INR 4,042 to 23,453 ( USD 60 - 350) as OOPE. Nearly 62% patients incurred CHE, and 30% reported distress financing. The odds of CHE (OR: 25.39, p-value: <0.001) and distress financing (OR: 15.37, p-value: 0.001) were significantly higher in poorest-income quintile. The HBP cost varies from INR 45,364 to 64,422 (USD 676 - 960) for brachytherapy and radiotherapy respectively.
conclusionCervical cancer treatment leads to high OOPE in India, which imposes financial hardship, especially for the poorest. The coverage of risk pooling mechanisms like PHFIs should be enhanced. The findings of our study should be used to set the reimbursement rates of providing cervical cancer treatment under PFHI schemes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.